In a small, dimly lit room in a clinic in London, a patient lies on a bed, guided by a trained therapist. After a preparatory conversation, they are given an eye mask and a controlled dose of psilocybin, the active compound in magic mushrooms. As the substance takes effect, rigid patterns of thought begin to loosen—a process that could offer relief to millions of Europeans living with treatment-resistant depression or post-traumatic stress disorder (PTSD).
This scenario, once confined to the fringes of psychiatry, is now at the centre of a rapidly expanding field of research. With over a billion people worldwide affected by mental health disorders, according to the World Health Organization, the urgency for new treatments has never been greater. Dr Liliana Galindo, an assistant professor at the University of Cambridge's psychiatry department, notes that psychiatry has seen few novel treatments in recent decades. “What psychedelics are bringing is the opportunity to present new treatments for people that don't respond to the usual treatments,” she explains.
How Psychedelics Work in the Brain
Psychedelics such as psilocybin, DMT, MDMA, and LSD bind to serotonin receptors, profoundly altering perception and mood. Each compound varies in intensity and duration, with different ones being tested for specific conditions. Psilocybin has generated the most promising results for depression. Compass Pathways' synthetic formulation, COMP360, has completed phase three clinical trials, and an application to the US Food and Drug Administration is expected soon. “Potentially, this could be the very first psychedelic treatment that will be legal and approved,” Galindo says.
Traditional treatments—talk therapy and antidepressants—are effective for many, but a significant minority do not respond. Galindo describes how depression creates “rigid cognitions,” or negative thought patterns that become entrenched over years. Psychedelics, she says, can disrupt these cognitive ruts. She uses a skiing analogy: “You usually go for a certain pathway, and because the pathway has a specific mark, it is really difficult to go outside of it. But psilocybin allows fresh snow that makes it easier to explore different pathways.”
Research from Imperial College London, a leader in the field, shows that a single dose of psilocybin can prompt anatomical changes in the brain. MDMA, meanwhile, enhances empathy and openness, making it effective for PTSD by allowing patients to revisit traumatic memories in a safe setting. “It facilitates a period where people can rethink, reframe, and process their trauma,” Galindo says. “This is the reason psychedelics are bringing such a big revolution to mental health—they aim to treat the core rather than only the symptoms.”
Regulatory and Social Hurdles in Europe
Despite the evidence, psychedelics remain illegal in most European countries. In the United Kingdom, psilocybin is a Class A drug, requiring a special Home Office licence for research. “This is not only expensive, but takes a long time, and is definitely affecting the amount of research that could be happening,” Galindo says. Similar restrictions exist across the EU, though some member states, like the Netherlands and Portugal, have more permissive policies.
Stigma also persists, with psychedelics often associated with party culture and potential risks. Galindo stresses the importance of controlled settings: “You need to take care of all the details of the environment—sound, lights—and the patient is supported by a trained therapist the entire time. These drugs are powerful tools, but if not given in the right setting, they could come with more side effects.”
The European mental health crisis, exacerbated by the pandemic and ongoing geopolitical tensions, has intensified the search for alternatives. As research progresses, the continent faces a delicate balance between scientific promise and regulatory caution. The path to approval will require not only clinical evidence but also a shift in public perception and legal frameworks.
For now, the potential is clear. As Galindo puts it, “We are at a turning point. The question is not whether psychedelics work, but how we can integrate them safely into healthcare systems.”
